INDOCO REMEDIES
|
INDOCO REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 10.68 | 15.44 | 16.80 | 10.10 | 2.62 |
CEPS(Rs) | 20.49 | 23.10 | 25.37 | 18.03 | 10.30 |
DPS(Rs) | 1.50 | 2.25 | 2.25 | 1.50 | 0.30 |
Book NAV/Share(Rs) | 120.02 | 111.51 | 98.17 | 83.45 | 73.75 |
Tax Rate(%) | 28.57 | 26.22 | 34.57 | 29.51 | 15.59 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 13.01 | 17.14 | 21.17 | 17.59 | 10.92 |
EBIT Margin(%) | 9.62 | 13.05 | 16.27 | 12.42 | 4.95 |
Pre Tax Margin(%) | 7.47 | 11.55 | 15.35 | 10.63 | 2.58 |
PAT Margin (%) | 5.34 | 8.53 | 10.05 | 7.49 | 2.18 |
Cash Profit Margin (%) | 10.39 | 12.76 | 15.17 | 13.38 | 8.58 |
Performance Ratios | |||||
ROA(%) | 4.99 | 8.64 | 10.63 | 7.23 | 1.96 |
ROE(%) | 9.09 | 14.72 | 18.50 | 12.85 | 3.60 |
ROCE(%) | 11.25 | 17.48 | 23.03 | 15.67 | 5.78 |
Asset Turnover(x) | 0.93 | 1.01 | 1.06 | 0.96 | 0.90 |
Sales/Fixed Asset(x) | 1.13 | 1.26 | 1.28 | 1.08 | 1.07 |
Working Capital/Sales(x) | 5.31 | 4.35 | 4.42 | 5.76 | 10.63 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.88 | 0.80 | 0.78 | 0.93 | 0.93 |
Receivable days | 76.04 | 70.89 | 62.90 | 65.26 | 66.96 |
Inventory Days | 68.19 | 69.62 | 64.95 | 65.58 | 64.61 |
Payable days | 90.44 | 89.88 | 98.49 | 143.70 | 185.76 |
Valuation Parameters | |||||
PER(x) | 30.76 | 21.09 | 22.42 | 28.57 | 79.99 |
PCE(x) | 16.03 | 14.09 | 14.84 | 16.00 | 20.32 |
Price/Book(x) | 2.74 | 2.92 | 3.84 | 3.46 | 2.84 |
Yield(%) | 0.46 | 0.69 | 0.60 | 0.52 | 0.14 |
EV/Net Sales(x) | 2.01 | 1.98 | 2.40 | 2.34 | 1.95 |
EV/Core EBITDA(x) | 14.34 | 11.45 | 11.21 | 12.77 | 17.14 |
EV/EBIT(x) | 20.93 | 15.16 | 14.74 | 18.82 | 39.27 |
EV/CE(x) | 2.07 | 1.93 | 2.34 | 2.18 | 1.74 |
M Cap / Sales | 1.67 | 1.80 | 2.25 | 2.14 | 1.74 |
Growth Ratio | |||||
Net Sales Growth(%) | 8.91 | 8.30 | 24.10 | 12.19 | 14.26 |
Core EBITDA Growth(%) | -11.54 | -12.51 | 44.98 | 80.98 | 50.75 |
EBIT Growth(%) | -19.75 | -13.12 | 62.53 | 181.36 | 365.47 |
PAT Growth(%) | -31.81 | -8.11 | 66.37 | 285.80 | 930.49 |
EPS Growth(%) | -30.81 | -8.11 | 66.37 | 285.80 | 930.59 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.59 | 0.31 | 0.27 | 0.34 | 0.39 |
Current Ratio(x) | 1.53 | 1.90 | 1.67 | 1.53 | 1.23 |
Quick Ratio(x) | 0.98 | 1.14 | 1.07 | 0.95 | 0.77 |
Interest Cover(x) | 4.48 | 8.70 | 17.73 | 6.93 | 2.09 |
Total Debt/Mcap(x) | 0.22 | 0.10 | 0.07 | 0.10 | 0.14 |
Compare Financial Ratios of peers of INDOCO REMEDIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDOCO REMEDIES | ₹3,115.4 Cr | 1.7% | 5.2% | -15.8% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹450,595.0 Cr | 0.9% | 4.4% | 50% | Stock Analytics | |
DIVIS LABORATORIES | ₹163,089.0 Cr | 4.6% | -1.1% | 55.6% | Stock Analytics | |
CIPLA | ₹124,175.0 Cr | 2.1% | 0.2% | 22.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹114,625.0 Cr | -1.1% | 12.1% | 18.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹99,672.5 Cr | 1.8% | 0.9% | 41.3% | Stock Analytics |
INDOCO REMEDIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDOCO REMEDIES | 1.7% |
5.2% |
-15.8% |
SENSEX | 1.9% |
-0.4% |
10.4% |
You may also like the below Video Courses